Skip to content

Mathieu Fradet

5 papers in the library · 10 citations · publishing 2024-2026

Papers

Psilocybin and hallucinogenic mushrooms.

CNS spectrums December 1, 2024 Mathieu Fradet, Carlton M Kelly, Anna J Donnelly et al. 10 citations

Psilocybin therapy shows promise as a new treatment for depression and other mental health disorders. The chapter reviews recent data on its safety and efficacy, describes how the therapy is delivered and its subjective effects, and outlines current understanding of psilocybin's pharmacology and neurobiological effects. Other psychedelic substances with therapeutic potential are also briefly discussed.

DOI: 10.1017/s1092852924002487 Full text Magic mushrooms Treatment-resistant depression Psychedelic therapy Psychedelic-assisted therapy +4

Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression.

Journal of affective disorders November 1, 2026 Carlton M Kelly, Mathieu Fradet, Catherine M Bostian et al.

A single 25-mg dose of psilocybin with psychological support was associated with sustained improvements in anxiety, quality of life, functioning, and PTSD symptoms in 15 veterans with treatment-resistant depression. Anxiety scores dropped 59% from baseline at three weeks and remained lower through 12 months. Quality of life increased 24% and functional impairment decreased 46% at three weeks, though these effects were no longer statistically significant after accounting for concurrent improvements in depression. PTSD symptom reductions were observed at all timepoints. Acute subjective experiences did not correlate with treatment response. The study is limited by its small sample and open-label design.

DOI: 10.1016/j.jad.2026.122063 Full text Anxiety Psilocybin Treatment-resistant depression Posttraumatic stress disorder +1

Increasing the Evaluation and Reporting Rigor of Psychotherapy Interventions in Treatments Involving Psychedelics

Psychoactives June 29, 2025 Mathieu Fradet

Psychedelic treatments show promise for mental health conditions but are delivered inconsistently across studies and clinics. Beyond differences in substances and doses, the psychotherapeutic interventions themselves vary greatly. A systematic review of clinical trials using psilocybin for depression reveals that the exact nature of these therapies is poorly defined in most scientific papers. This lack of documentation hinders the dissemination and improvement of evidence-based protocols. The field would benefit from optimized psychotherapeutic methods, but insufficient reporting currently blocks progress. The article offers ideas to encourage better documentation and advancement of research on psychedelic-assisted therapies.

DOI: 10.3390/psychoactives4030021 Psychotherapist Psychological intervention Psychology Rigour +4

Psychedelics for Depression: Between Hopes and Uncertainties.

Focus (Am Psychiatr Publ) April 15, 2025 Trisha Suppes, Mathieu Fradet

The use of psychedelics to treat depression is surrounded by both optimism and unresolved questions. The text examines the gap between high expectations and the current evidence base, highlighting that while early results are promising, significant uncertainties remain about efficacy, safety, and mechanisms of action. It calls for cautious interpretation and further rigorous research before these substances can be considered a standard treatment.

DOI: 10.1176/appi.focus.20250005 Full text